Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Prospects to win concessions on EU pharmaceutical legislation overhaul strengthened, says GlobalData

The potential for German Chancellor Olaf Scholz’s government to secure pro-pharmaceutical industry concessions related to the proposed overhaul of EU pharmaceutical legislation may have received a significant boost. A recent report from the German Federal Ministry of Health has raised substantial concerns regarding critical elements of the reform strategy, further underscoring the need for careful […]
Read more

More pricing pain for pharma as new legislation expands scope of Inflation Reduction Act, says GlobalData

The global pharma industry is bracing itself for more headaches in its most profitable market as US House Democratic health leaders introduce new legislation, which would expand the Inflation Reduction Act and further lower prescription drug prices. House Democrats Frank Pallone Jr., Richard Neal, and Robert Scott unveiled the Lowering Drug Costs for American Families […]
Read more

Shanghai Junshi renal cell carcinoma drug toripalimab to get first-mover advantage in China PD-1 market, says GlobalData

Shanghai Junshi Biosciences supplemental new drug application (sNDA) for toripalimab, the company’s anti-PD-1 monoclonal antibody, in combination with axitinib for the first-line treatment of patients with unresectable or metastatic renal cell carcinoma (RCC), has been accepted by the National Medical Products Administration (NMPA). Following the approval, the drug is expected to get a first-mover advantage […]
Read more

Zurzuvae provides breakthrough for postpartum depression but misses out on larger MDD patient population, says GlobalData

Following the news that the FDA granted approval for Sage Therapeutics and Biogen’s novel antidepressant Zurzuvae (zuranolone) for the treatment of postpartum depression (PPD) but rejected the drug for the treatment of major depressive disorder (MDD), issuing a complete response letter (CRL); Philippa Salter, Senior Neurology Analyst at GlobalData, offers her view: “Zurzuvae is a […]
Read more

NASH market holds enormous untapped potential, says GlobalData

The prevalence of nonalcoholic steatohepatitis (NASH), a more advanced stage of nonalcoholic fatty liver disease (NAFLD), continues to increase. Following the receipt of a complete response letter (CRL) from the FDA for its farnesoid X receptor (FXR) agonist, obeticholic acid (OCA), in NASH, Intercept Pharmaceuticals has joined the list of companies who have failed to […]
Read more

Zynlonta’s clinical failure will increase opportunities for competing ADCs in DLBCL, says GlobalData

ADC Therapeutics recently announced plans to discontinue the Phase II LOTIS-9 trial investigating the combination of Zynlonta and rituximab in unfit or frail previously untreated diffuse large B-cell lymphoma (DLBCL) patients following reports of excessive respiratory-related treatment-emergent adverse events. The company disclosed that it will cease its investigation of the Zynlonta-rituximab regimen in this patient […]
Read more

Janssen’s JNJ-2113 holds potential to become leading treatment for psoriasis, says GlobalData

Janssen Pharmaceuticals recently announced its latest clinical trial results of JNJ-2113, the novel, first-in-class oral interleukin 23 receptor (IL-23R) antagonist peptide in adult patients with moderate-to-severe plaque psoriasis (PsO). Representing an innovative oral therapy that specifically targets and binds with high affinity to the IL-23R, JNJ-2113 is set to become a leading treatment for this […]
Read more

AI appreciation in clinical practice comes with hands-on experience and understanding of technology, says GlobalData

As artificial intelligence (AI) increasingly finds its way into healthcare, physicians recognize the true value of its advantages in clinical practice more prominently after successful implementation and regular usage in their day-to-day work, according to a survey by  GlobalData, a leading data and analytics company. A GlobalData survey*, “AI in Clinical Practice – Physician Perspective […]
Read more

Positive FDA meeting could allow Iovance gain accelerated approval for TIL therapy, says GlobalData

On July 10, Iovance Biotherapeutics announced they received positive feedback from the FDA on the design of their Phase II IOV-LUN-202 study evaluating tumor-infiltrating lymphocyte (TIL) therapy LN-145 in patients with advanced non-small cell lung cancer (NSCLC). Following their Pre-Phase III meeting with the agency, the therapy may be acceptable for accelerated approval, says GlobalData, […]
Read more

Almost half of healthcare industry professionals endorse AI in clinical practice, reveals GlobalData survey

Artificial intelligence (AI) is increasingly becoming embedded in the provision of healthcare. Against this backdrop, 49% of healthcare industry professionals with prior AI experience showed strong endorsement for its use in clinical practice and administrative tasks, according to a survey* by GlobalData, a leading data and analytics company. GlobalData’s latest Thematic Intelligence report, “AI in […]
Read more

India’s rising profile in clinical trials sparks urgency to raise public awareness, says GlobalData

India is emerging as a key destination for clinical trials due to its large, diverse population and liberalized regulatory landscape. Despite the increase in the number of clinical trials initiated by either domestic or multinational pharmaceutical companies in recent years, awareness about the trials is low. Addressing the issue through strategic approaches is a pressing […]
Read more

M&A activity of pharma CMOs will continue despite challenging borrowing environment, says GlobalData

The mergers and acquisitions (M&A) activity of well-capitalized pharmaceutical contract manufacturing organizations (CMOs) is set to continue over the coming years despite a challenging borrowing environment due to rising inflation and interest rates, according to GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘M&A in the Contract Manufacturing Industry: Implications and Outlook – […]
Read more

Phase III trial results could strengthen Ocrevus’s position in multiple sclerosis market, says GlobalData

Genentech recently announced positive results from its phase III trial, OCARINA II (NCT05232825), investigating the efficacy of Ocrevus (ocrelizumab) as a subcutaneous injection, administered twice yearly for ten minutes, in patients diagnosed with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Roche announced the trial met all of the primary and secondary endpoints, […]
Read more
1 … 30 31 32 33 34 … 108